Quotes

Back To Menu

Nippon India Pharma Fund (Bonus) Equity - Pharma

INVEST

Plan: OPEN | Option: Growth | Sailesh Raj Bhan

24 Jul 26 | 12:00 AM

556.11 -1.23 (-0.22%)

  • Underperforms

    5.29%

    Return (1Y)

    underperformed BSE Healthcare TRI by -43.02%

  • More Volatile

    0.79%

    Standard Deviation (1Y)

    Higher Equity - Pharma by 0.79%

  • Inconsistent

    /0

    Months

    Has underperformed Equity - Pharma

  • Value research rating

    Not Rated

Stock Composition

NAV

Critical Parameters

Everyone of us wants to create wealth by investing in top funds. Have a look at the key parameters that you need to check before deciding to invest in a mutual fund.

Returns

In last 1 year Nippon India Pharma Fund (Bonus), has underperformed by -43.02% (CAGR difference)

5.29%

Underperforms

This is Alpha

Performance Chart for Rs

Invested in

26 Jul 2025

Risk

In last 1 year , the volatility of Nippon India Pharma Fund (Bonus) is Higher than by 0.79%

0.79%

More Volatile

Risk Meter

Peer Comparison on Risk - Return

Consistency

For out of Last 0 Months, i.e 0% of the times It underperformed its benchmark, Equity - Pharma

Consistency Meter

Outperforming Stocks Vs. Underperforming Stocks

Based on the last 1year analysis, currently there are, the benchmark the benchmark

View Stock Composition